NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

According to the pub, unmethylated MGMT aint doing so bad. The literature suggests that mOS for unmethylated SOC is 12.7 months. The blended mOS is 19.8 months. This is a delta of 7 months. For methylated MGMT, the literature suggests SOC mOS of 21.7 months (although a 35 patient study in 2015 stated about 29 months) and blended results were 34.7 months, which is a delta of 13 months. Methylated delta is about double that of unmethylated on blended results. Where does mesenchymal fit in the M+/M- category? Like methylated it is highly heterogeneous and mutational. But like unmethylated, mesenchymal is highly aggressive. Does mesenchymal overlap in these two categories? That might explain the delta in unmethylated to some extent. Seems to me that the prognosis is quite good for unmethylated and extremely encouraging for methylated which comprises at least 40% of the ITT population and 42% of the counted population taking into consideration the 38 patients who were not categorised as M+ or M-. JMHO.